Decentralized Manufacturing for Cell Therapies
Information
3pm Chair Introduction
Miguel Forte, Chief Executive Officer, Kiji Therapeutics, President-Elect, ISCT
3.05pm Presentation Title: Point of Care Manufacturing at an Academic Center: Increasing Accessibility to Cell Therapies
- Discuss benefits of point of care manufacturing over traditional third-party manufacturing paradigms
- Review outcomes with CliniMACS Prodigy Manufacturing at an Academic Center
Nirav Shah, Associate Professor of Medicine, Medical College Wisconsin
3.20pm Presentation: Enabling Decentralized Manufacturing By Metabolic Sensing And Control, Machine Learning And AI. The ADVA X3 Case Study
- Taking the human error and variation out of cell therapy manufacturing
- Automating cell therapy manufacturing based on metabolic sensing and feedback loops.
- Ensuring the correct process outcome using online data and machine learning.
- Process optimization and predictability using AI
- Adva X3 CAR T case studies
Ohad Karnieli, Chief Executive Officer, ADVA
3.35pm Presentation: Joining Forces For Distributed Manufacturing - Here We Are
- Why
- How
- Who
- Status
Dorothea Ledergerber, Chief Technical Officer, Tigen
3.50pm Presentation Title: The Inevitability of Decentralizing Advanced Therapies Manufacturing (and the tug-of-war on the way to this future)
- Where is the line between decentralized, distributed, and point-of-care manufacturing?
- Does the point-of-care manufacturing model require hospitals to manufacture?
- Does decentralized or POC manufacturing require a different biopharma business model?
Lee Buckler, Senior Vice President, Blood Centers for America
4.05pm Panel Discussion
Joined by all session participants
